Research programme: growth hormone receptor antagonists - Amolyt Pharma/PeptiDream
Alternative Names: AZP-38XXLatest Information Update: 18 Jul 2024
At a glance
- Originator PeptiDream
- Developer Amolyt Pharma; PeptiDream
- Class Antisecretories; Peptides
- Mechanism of Action Growth hormone-releasing hormone inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Acromegaly
Most Recent Events
- 15 Jul 2024 Amolyt Pharma has been acquired by AstraZeneca
- 09 Sep 2021 Amolyt Pharma in-licenses portfolio of macrocyclic peptide growth hormone receptor antagonists from PeptiDream
- 08 Dec 2020 PeptiDream and Amolyt Pharma entered into a strategic partnership and global license option agreement for AZP 3813 for the treatment of acromegaly